NCT07014475尚未招募不适用
Efficacy of the Ranger Drug-Coated Balloon in Treating Below-the-Knee Lesions in Patients With Chronic Limb-Threatening Ischemia
First Affiliated Hospital, Sun Yat-Sen University1 个研究点 分布在 1 个国家目标入组 700 人开始时间: 2025年6月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 700
- 试验地点
- 1
- 主要终点
- Major Adverse Events (MAEs)
研究概览
简要总结
This is a prospective, multicenter, observational study designed to evaluate the clinical outcomes of the Ranger™ SL paclitaxel-coated balloon, a type of drug-coated balloon (DCB), in the treatment of below-the-knee (BTK) lesions in patients with chronic limb-threatening ischemia (CLTI) in China. All enrolled patients will be followed for six months. Patients diagnosed with CLTI who undergo treatment with the Ranger DCB will be included in the study. The primary outcome is the incidence of major adverse events (MAEs).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years, gender is not limited
- •The patient agreed to participate in the CEIBA study and signed the written informed consent
- •Diagnosis of chronic limb-threatening ischemia (Rutherford category 4-6)
- •Gangrene involving any part of the lower extremities or feet, with exclusion of patients who have:
- •4.1 Pure venous ulcers 4.2 Pure traumatic wounds 4.3 Acute limb ischemia (symptoms present for 2 weeks or less) 4.4 Embolic disease 4.5 Non-atherosclerotic chronic lower extremity vascular diseases (e.g., vasculitis, Buerger's disease, radiation arteritis)
- •Outflow Tract Requirement: At least one direct or indirect, unobstructed outflow vessel in the submalleolar segment of the target limb planned for revascularization.
- •Lesion Type:
- •6.1 Unobstructed blood flow in the suprapopliteal access pathway (including inflow vessels that have been recanalized via staged or concurrent endovascular intervention or hybrid surgery).
- •6.2 Sub-knee stenotic lesions ≥ 5 cm in length with ≥ 70% diameter reduction. 6.3 Sub-knee occlusive lesions ≥ 1 cm in length. 6.4 Two separate lesions with a minimum 3 cm interval between them may be considered as a single lesion for study inclusion purposes.
排除标准
- •Presence of life-threatening diseases or comorbidities with an expected life expectancy of less than 1 year.
- •Concurrent participation in another interventional clinical trial requiring informed consent.
- •Diagnosis of Alzheimer's disease.
- •Hematologic disorders or known bleeding tendency.
- •Contraindications to antiplatelet or anticoagulant therapy.
- •Known allergy to contrast agents that cannot be managed with standard premedication (e.g., steroids).
- •Deficiency or dysfunction of protein C, protein S, or antithrombin III (ATIII).
- •New York Heart Association (NYHA) Class III or IV heart failure.
- •Pregnancy or lactation.
- •Prior suprapatellar or infrapatellar amputation of the target limb.
- •Presence of aneurysm, perforation, dissection, or other target vessel injury requiring intervention.
- •Presence of other comorbid conditions (unrelated to the index disease) that affect walking function.
- •History of cardiovascular events within the past 3 months, including nonfatal myocardial infarction, unstable angina, stable angina, nonfatal ischemic stroke, or hemorrhagic stroke.
- •Clinically significant liver or renal dysfunction, as determined by the investigator.
- •Any other condition that, in the opinion of the investigator, would interfere with study treatment or functional assessments.
结局指标
主要结局
Major Adverse Events (MAEs)
时间窗: 1 month; 3 months; 6 months
Composite of target lesion revascularization (TLR), target limb amputation, and all-cause mortality.
次要结局
- Late Lumen Loss (LLL)(1 month; 3 months; 6 months)
- Amputation-Free Survival (AFS)(1 month; 3 months; 6 months)
- Limb Salvage(1 month; 3 months; 6 months)
- Postoperative Complications(During procedure and hospitalization (up to 7 days post-procedure))
- Quality of Life (QoL)(Baseline, 1 month; 3 months; 6 months)
- Rutherford Classification(Baseline, 1 month; 3 months; 6 months)
研究者
Chang Guangqi
Clinical Professor
First Affiliated Hospital, Sun Yat-Sen University
研究点 (1)
Loading locations...
相似试验
招募中
不适用
ACOART Intracranial ISR Pilot:Intracranial DCB in the Treatment of Intracranial In-stent RestenosisIntracranial AtherosclerosisStrokeNCT04627870Acotec Scientific Co., Ltd20
Unknown
不适用
A Trail of Drug-coated Balloon Treating Below The Knee Arterial DiseasesPeripheral Artery DiseaseNCT05415995Zhejiang Zylox Medical Device Co., Ltd.202
已完成
不适用
Investigation of the Ringer Perfusion Balloon Catheter (Ringer PTCA)Coronary StenosisNCT04862689Vascular Solutions LLC60
已完成
不适用
Clinical Investigation of the GORE® Drug-Coated PTA Balloon Catheter (GORE® DCB Catheter)PADNCT02907203W.L.Gore & Associates52
已完成
3 期
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon AngioplastyPeripheral Artery DiseaseArtery Diseases, PeripheralPlaque, AtheroscleroticOcclusive Arterial DiseaseAtherosclerosisNCT03064126Boston Scientific Corporation440